Methods and agents for modulating protocadherin-18 activity
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 7, 2017
Grant Date -
Apr 3, 2014
app pub date -
Oct 2, 2013
filing date -
Oct 2, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Screening assays and methods of using same for screening to identify modulator agents or compounds that affect pcdh18 mediated inhibition of T cell effector function are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate pcdh18 mediated inhibition of T cell effector function are also encompassed. Methods for modulating pcdh18 mediated inhibition of T cell effector function using agents identified using assays described herein in pharmaceutical and immunogenic compositions are also envisioned. Adenocarcinoma is an exemplary tumor type that expresses pcdh18 and for which such pharmaceutical and immunogenic compositions would confer benefit to patients. Also encompassed are methods for reducing pcdh18 mediated inhibition of T cell effector function so as to achieve more effective T cell responses to pcdh18 expressing tumors.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully